Improving blood vessel repair after pediatric ARDS
Official title: Improving endothelial repair in pediatric ARDS
Funded at University of Arizona · NIH-11444432 · Data updated 2026-11-12
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | September 1, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $748,677 |
| NIH project number | 1R01HL182688-01A1 |
| Project ID | NIH-11444432 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children with a history of PARDS or at risk for PARDS may benefit if the therapy proves safe and effective.
✕Less likely to help
Children without ARDS or without a lung injury history may not benefit from this specific endothelial-targeted therapy.
What this research studies
This project focuses on understanding how to restore blood vessel growth in the lungs after pediatric ARDS, so children can recover their normal lung development. Researchers are developing nanoparticle carriers that specifically reach lung endothelial cells to deliver drugs or genetic messages. The work emphasizes safety in inflammatory lung conditions and seeks a targeted, non-toxic approach to boost endothelial repair. If successful, this could complement current treatments and help prevent long-term lung problems.
Why it matters
Potential benefit: Could improve lung healing in children after ARDS and reduce risk of long-term lung disease.
How similar studies have gone: Prior endothelial-targeted nanoparticle approaches show promise in delivering therapy to lung tissue, but lung-specific targeting and pediatric application remain under investigation.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Kalinichenko, Vladimir — University of Arizona
- Study coordinator: Kalinichenko, Vladimir
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
-
Innovative immune therapy with antibiotics to treat deadly inflammation in sepsis and ARDS in older adults
A new approach combines an antibiotic strategy with a special immune-based treatment to help older patients who have sepsis or ARDS from severe bacterial infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.